Dr. Siefker-Radtke discusses new mUC study results - Norse and THOR

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Dr. Arlene O. Siefker-Radtke (US) from the Depart. of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. She answers questions about the recent ASCO23 presentations on metastatic urothelial cancer (mUC), where new results of the phase II Norse study, and the phase III THOR study were shared.Phase II Norse study:Dr. Siefker-Radtke elaborates on the study rational and pleasing r...